European study confirms safety and efficacy of Zolgensma in ADS
This European study included patients with more severe cases of spinal muscular atrophy than a similar study conducted in the United States. Zolgensma (onasemnogene abeparvovec-xioi) shows efficacy in patients with severe spinal muscular atrophy (SMA), according to results recently published in The Lancet Neurology. The results of a phase 3Read More →






